SOX2 and esophageal cancer: We also found that in early esophageal cancer patients, as was described in Table 4, the stem signatures-associated antibody indicators of SOX2 showed the specificity and sensitivity of 80% and 89.9% respectively in the ROC curve, when referring to stage I esophageal cancer patients (Figure 5(B)).